Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

17.80USD
17 Nov 2017
Change (% chg)

$0.55 (+3.19%)
Prev Close
$17.25
Open
$17.10
Day's High
$18.00
Day's Low
$17.00
Volume
1,030,693
Avg. Vol
858,242
52-wk High
$33.00
52-wk Low
$13.60

Chart for

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $832.10
Shares Outstanding(Mil.): 46.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Nov 17 2017

Acorda reports five deaths in Parkinson's trial, shares plunge

Acorda Therapeutics Inc said five people died in trials for its Parkinson's disease drug, the latest in a series of setbacks for the drugmaker, sending its shares down 38 percent.

Nov 15 2017

UPDATE 4-Acorda reports five deaths in Parkinson's trial, shares plunge

* Shares tank nearly 40 pct (Recasts, adds CEO and analyst comments, updates shares)

Nov 15 2017

BRIEF-Acorda provides update on tozadenant development program

* Identified cases of agranulocytosis, possibly drug-related, in some cases associated with sepsis and death​

Nov 15 2017

Acorda halts enrollment in Parkinson's disease trial

Nov 15 Acorda Therapeutics Inc said on Wednesday it has halted enroling patients in a late-stage trial testing its drug to treat Parkinson's disease, after reports of cases related to neutropenia, sepsis and death.

Nov 15 2017

BRIEF-Acorda Therapeutics reports Q3 non-gaap earnings per share $0.43

* Q3 revenue $141.1 million versus I/B/E/S view $150.6 million

Oct 31 2017

BRIEF-Acorda Q3 GAAP loss per share $0.55

* Acorda provides financial and pipeline update for third quarter 2017

Oct 31 2017

BRIEF-Acorda adopts Shareholder Rights Plan

* Acorda Therapeutics - adopted Shareholder Rights Plan, declared a dividend distribution of 1 preferred share purchase right on each outstanding share

Sep 01 2017

BRIEF-Scopia Capital Management ups its stake in Acorda Therapeutics to 18.2 pct from previous stake of 16.5 pct

* Scopia Capital Management reports 18.2 pct stake in Acorda Therapeutics Inc as of Aug 29 versus 16.5 percent stake as of Aug 4 - SEC filing Source text: (http://bit.ly/2wm9kpl) Further company coverage:

Aug 31 2017

BRIEF-Acorda receives refusal to file letter from FDA for Inbrija maketing application

* Acorda receives refusal to file letter from FDA for Inbrija™ (CVT-301, Levodopa inhalation powder) new drug application

Aug 29 2017

Earnings vs. Estimates